Given previous success with therapeutic agents targeting the RTK/RAS/RAF and PI3K/mTOR pathways in other malignancies and multiple emerging investigational agents in SCLC, alterations in these pathways may predict sensitivity to targeted therapies 23-25. Here, MTOR is linked to small cell lung carcinoma.